ClinicalTrials.govclosed
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
ClinicalTrials.gov study NCT04082364. IPD Sharing: NO. Countries: 9. Publications: 1.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8